December 14, 2024 05:23 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bengaluru techie suicide: Karnataka Police issues summons to wife Nikita, her family members | French President Macron appoints centrist leader Francois Bayrou as new Prime Minister | Congress always prioritised personal interest over Constitution: Rajnath Singh | Jaishankar calls attack on Hindus in Bangladesh 'a source of concern' | Allu Arjun arrested over woman's death in stampede during Pushpa 2 premiere show | RBI receives bomb threat in Russian language, case filed | UP teenager kills mother, lives with body for 5 days | At least six people including a child killed in Tamil Nadu hospital fire | Amid Atul Subhash row, SC says mere harassment is not enough to prove abetment to suicide | India's D Gukesh becomes youngest ever world champion in chess

Government to roll out new drug for treatment of drug-resistant TB

| | Mar 21, 2016, at 08:09 pm
New Delhi, Mar 21 (IBNS) The central government is launching a drug called Bedaquiline on Monday for the treatment of multi-drug resistant tuberculosis (MDR TB) and extensively drug resistant tuberculosis (XDR TB), according to media reports.
Dubbed a 'miracle drug',  Bedaquiline (trade name Sirturo) is the first TB drug to be approved by Food and Drug Administration (FDA) in over 40 years.
 
The project is part of a coordinated programme between the government and Johnson & Johnson and has been rolled out under the Revised National Tuberculosis Control Programme; Janssen, a pharma unit under Johnson & Johnson  has manufactured the drug.
 
The drug will be made available in six public hospitals in Delhi, Mumbai, Chennai, Guwahati and Ahmedabad, according to reports.
 
In an exclusive interview to Times of India, Sanjiv Navangul, Janssen India MD, said, "We are ready with the roll-out of the drug through the government-run control programme, for which 600 patients will be enrolled across the country, over the next six to nine months, after the required tests. Upon the review of clinical data after two years, the access programme will be expanded nationwide."
 
As per World Health Organisation (WHO) Global Tuberculosis Report 2015, deaths due to TB were estimated in India to be 2,20,000 in 2014, which is higher than any other country.
 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.